June 20, 2021
Business News

Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

BROOKLYN, N.Y.–()–Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Christopher Rohde, Ph.D. to the Company’s Scientific Advisory Board, effective May 13, 2021.

Dr. Rohde is Co-Founder and Chief Technology Officer at Factor Bioscience. Dr. Rohde is also Co-Founder and President of Novellus Therapeutics. Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. Dr. Rohde is currently…

Click here to view the original article.

Related Posts

You might also like ...

Prime Day LEGO Deals (2021): Early LEGO Star Wars Millennium Falcon, Harry Potter & LEGO Boost Savings Ranked by Spending Lab
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
AON Splash Image
Drawing Tablet Prime Day Deals (2021): Best Early Wacom, HUION & More Deals Published by Save Bubble